{"id":"nicotine-rescue-method","safety":{"commonSideEffects":[{"rate":"10-20","effect":"Nausea"},{"rate":"5-15","effect":"Dizziness"},{"rate":"5-10","effect":"Headache"},{"rate":"10-20","effect":"Insomnia"},{"rate":"5-10","effect":"Irritability"},{"rate":"15-25","effect":"Local skin irritation (patch formulation)"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Nicotine binds to nicotinic acetylcholine receptors, particularly those containing α4β2 subunits, which are upregulated in chronic smokers. By providing exogenous nicotine through non-combustible delivery methods (patches, gum, lozenges, nasal spray, or inhalers), the drug satisfies the brain's dependence on nicotine while avoiding the harmful effects of tobacco smoke, thereby reducing withdrawal symptoms and facilitating smoking cessation.","oneSentence":"Nicotine acts as an agonist at nicotinic acetylcholine receptors in the central and peripheral nervous system to reduce cravings and withdrawal symptoms in tobacco dependence.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:35:01.675Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Nicotine dependence / smoking cessation"}]},"trialDetails":[{"nctId":"NCT05723588","phase":"PHASE2","title":"Neuroimaging Correlates and Feasibility of Transcranial Magnetic Stimulation (TMS) to Improve Smoking Cessation Outcomes in Veterans With Comorbid PTSD","status":"RECRUITING","sponsor":"VA Office of Research and Development","startDate":"2023-10-31","conditions":"Tobacco Use Disorder","enrollment":50},{"nctId":"NCT06442514","phase":"NA","title":"Pain and Smoking Study - Interactive Voice Response","status":"NOT_YET_RECRUITING","sponsor":"VA Office of Research and Development","startDate":"2026-03-30","conditions":"Smoking, Pain, Smoking Cessation","enrollment":220},{"nctId":"NCT04135937","phase":"PHASE4","title":"Mobile Evidence-Based Smoking Cessation for Veterans Living With HIV (MESH)","status":"COMPLETED","sponsor":"VA Office of Research and Development","startDate":"2019-11-18","conditions":"Human Immunodeficiency Virus, Smoking","enrollment":12},{"nctId":"NCT02245308","phase":"PHASE4","title":"Abstinence Reinforcement Therapy (ART) for Homeless Veteran Smokers","status":"COMPLETED","sponsor":"VA Office of Research and Development","startDate":"2014-10-01","conditions":"Tobacco Use Disorder, Homelessness","enrollment":133},{"nctId":"NCT02995915","phase":"PHASE4","title":"Mobile Contingency Management for Concurrent Abstinence From Alcohol and Smoking","status":"COMPLETED","sponsor":"Duke University","startDate":"2016-11","conditions":"Smoking Cessation, Alcohol Drinking","enrollment":45},{"nctId":"NCT02513069","phase":"NA","title":"Mobile Contingency Management for Smoking Cessation in Returning US Veterans","status":"COMPLETED","sponsor":"Duke University","startDate":"2015-01","conditions":"Smoking, Veterans","enrollment":291},{"nctId":"NCT02420015","phase":"PHASE4","title":"Mobile Health Technology to Enhance Abstinence in Smokers With Schizophrenia","status":"COMPLETED","sponsor":"Duke University","startDate":"2017-03-27","conditions":"Schizophrenia, Cigarette Smoking","enrollment":35},{"nctId":"NCT01901848","phase":"PHASE2, PHASE3","title":"CPT and Smoking Cessation","status":"COMPLETED","sponsor":"VA Office of Research and Development","startDate":"2013-12-11","conditions":"Stress Disorders, Post-Traumatic, Smoking","enrollment":69},{"nctId":"NCT01990079","phase":"NA","title":"Use of Technological Advances to Prevent Smoking Relapse Among Smokers With PTSD","status":"COMPLETED","sponsor":"Duke University","startDate":"2013-12","conditions":"PTSD, Smoking","enrollment":15},{"nctId":"NCT01789710","phase":"NA","title":"Contingency Management for Smoking Cessation in Homeless Smokers","status":"COMPLETED","sponsor":"Duke University","startDate":"2013-01","conditions":"Smoking, Homeless Persons","enrollment":25}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Nicorette"],"phase":"marketed","status":"active","brandName":"Nicotine rescue method","genericName":"Nicotine rescue method","companyName":"VA Office of Research and Development","companyId":"va-office-of-research-and-development","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Nicotine acts as an agonist at nicotinic acetylcholine receptors in the central and peripheral nervous system to reduce cravings and withdrawal symptoms in nicotine-dependent individuals. Used for Nicotine dependence and smoking cessation support.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}